The role of autophagy in cytotoxicity induced by new oncogenic B-Raf inhibitor UI-152 in v-Ha-ras transformed fibroblasts

Biochemical and Biophysical Research Communications

Volumn 417, Issue 2, 2012, Pages 857-863

  Ahn, Jun Ho ^a   Ahn, Soon Kil ^a,b   Lee, Michael ^a  

^a SolarLight Ltd   (South Korea)

^b YOUAI Co Ltd   (South Korea)

Author keywords

Apoptosis; Autophagy; B Raf inhibitor; Ras; UI 152

Indexed keywords

B RAF KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; SORAFENIB; UI 152; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; AUTOPHAGY; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN 3T3; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; FIBROBLAST; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CELL LINE, TRANSFORMED; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FIBROBLASTS; GENES, RAS; HUMANS; MICE; NIH 3T3 CELLS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PURINES; SULFONAMIDES; VERAPAMIL;

EID: 84855835533     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.061     Document Type: Article

References (29)

1. Solit D.B., Garraway L.A., Pratilas C.A., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
2. Davies H., Bignell G., Cox C., et al. Mutations of the B-Raf gene in human cancer. Nature 2002, 417:949-954.
3. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
4. Wan P.T., Garnett M.J., Roe S.M., et al. Cancer Genome Project, mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
5. Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br. J. Cancer 2006, 95:581-586.
6. Niculescu-Duvaz I., Roman E., Whittaker S.R., et al. Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J. Med. Chem. 2006, 49:407-416.
7. Takle A.K., Brown M.J., Davies S., et al. The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg. Med. Chem. Lett. 2006, 16:378-381.
8. Tsai J., Lee J.T., Wang W., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U S A 2008, 105:3041-3046.
9. Lee M., Ahn J.-H., Eum K.-H. The differences in biological properties between parental and v-Ha-ras transformed NIH3T3 cells. Cancer Res. Treat. 2009, 41:93-99.
10. Ahn J.-H., Kim Y.-K., Lee M. Decreased interaction of Raf-1 with its negative regulator Spry2 as a mechanism for acquired drug resistance. Biomol. Ther. 2011, 19:174-180.
11. Zheng B., Jeong J.H., Asara J.M., et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell 2009, 33:237-247.
12. Hatzivassiliou G., Song K., Yen I., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
13. Heidorn S.J., Milagre C., Whittaker S., et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
14. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
15. Rushworth L.K., Hindley A.D., O'Neill E., et al. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 2006, 26:2262-2272.
16. Burz C., Berindan-Neagoe I., Balacescu O., et al. Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol. 2009, 48:811-821.
17. Little A.S., Balmanno K., Sale M.J., et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci. Signal. 2011, 4:ra17.
18. Kondo Y., Kanzawa T., Sawaya R., et al. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 2005, 5:726-734.
19. Levine B. Unraveling the role of autophagy in cancer. Autophagy 2006, 2:65-66.
20. Kang C., Avery L. To be or not to be, the level of autophagy is the question: dual roles of autophagy in the survival response to starvation. Autophagy 2008, 4:82-84.
21. Mizushima N., Levine B., Cuervo A.M., et al. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
22. Karbowniczek M., Cash T., Cheung M., et al. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J. Biol. Chem. 2004, 279:29930-29937.
23. Maddodi N., Huang W., Havighurst T., et al. Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. J. Invest. Dermatol. 2010, 130:1657-1667.
24. Boya P., González-Polo R.A., Casares N., et al. Inhibition of macroautophagy triggers apoptosis. Mol. Cell. Biol. 2005, 25:1025-1040.
25. Shimizu S., Kanaseki T., Mizushima N., et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat. Cell Biol. 2004, 6:1221-1228.
26. Nazarian R., Shi H., Wang Q., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
27. Johannessen C.M., Boehm J.S., Kim S.Y., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
28. Glavinas H., Krajcsi P., Cserepes J., et al. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr. Drug Deliv. 2004, 1:27-42.
29. Gnoth M.J., Sandmann S., Engel K., et al. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. Drug Metab. Dispos. 2010, 38:1341-1346.